Arg145

Site Information
SrDYYASrSQGGSYG SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 9483284

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 )
Disease tissue studied:	testicular cancer ( 6 )
Relevant cell line - cell type - tissue:	brain ( 1 , 2 , 3 , 4 , 5 ) , F9 (testicular) ( 6 ) , MEF (fibroblast) ( 7 , 8 )

References
1	Guo A, et al. (2014) Immunoaffinity enrichment and mass spectrometry analysis of protein methylation. Mol Cell Proteomics 13, 372-87 24129315 Curated Info
2	Guo A (2013) CST Curation Set: 18334; Year: ; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Curated Info
3	Guo A (2013) CST Curation Set: 18335; Year: ; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Curated Info
4	Guo A (2013) CST Curation Set: 18336; Year: ; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Curated Info
5	Guo A (2013) CST Curation Set: 18337; Year: ; Biosample/Treatment: tissue, brain/-; Disease: -; SILAC: -; Curated Info
6	Zhou J (2010) CST Curation Set: 9111; Year: 2010; Biosample/Treatment: cell line, F9/untreated; Disease: testicular cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
7	Zhou J (2009) CST Curation Set: 6953; Year: 2009; Biosample/Treatment: cell line, MEF/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info
8	Zhou J (2009) CST Curation Set: 6952; Year: 2009; Biosample/Treatment: cell line, MEF/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: m1R Curated Info